KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hims & Hers Health (HIMS) Cash & Equivalents (2019 - 2025)

Hims & Hers Health's Cash & Equivalents history spans 7 years, with the latest figure at $228.6 million for Q4 2025.

  • For Q4 2025, Cash & Equivalents rose 3.64% year-over-year to $228.6 million; the TTM value through Dec 2025 reached $228.6 million, up 3.64%, while the annual FY2025 figure was $228.6 million, 3.64% up from the prior year.
  • Cash & Equivalents for Q4 2025 was $228.6 million at Hims & Hers Health, down from $345.8 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $1.1 billion in Q2 2025 and bottomed at $46.8 million in Q4 2022.
  • The 5-year median for Cash & Equivalents is $92.4 million (2021), against an average of $170.1 million.
  • The largest annual shift saw Cash & Equivalents soared 7633.13% in 2021 before it crashed 48.64% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $71.8 million in 2021, then tumbled by 34.84% to $46.8 million in 2022, then surged by 106.67% to $96.7 million in 2023, then surged by 128.2% to $220.6 million in 2024, then increased by 3.64% to $228.6 million in 2025.
  • Per Business Quant, the three most recent readings for HIMS's Cash & Equivalents are $228.6 million (Q4 2025), $345.8 million (Q3 2025), and $1.1 billion (Q2 2025).